BCG vaccination is associated with a reduced mortality from nonmycobacterial infections. This is likely to be mediated by a combination of innate-immune memory ("trained immunity") and heterologous effects on adaptive immunity. As such, BCG could be used to boost host immunity but not in immunocompromised hosts, as it is a live, attenuated vaccine. Therefore, we assessed whether killed gBCG has similar potentiating effects. In an in vitro model of trained immunity, human monocytes were incubated with gBCG for 24 h and restimulated after 6 d. Cytokine production and the role of pattern recognition receptors and histone methylation markers were assessed. The in vivo effects of gBCG vaccination were studied in a proof-of-principle trial in 15 healthy volunteers. gBCG induced trained immunity in vitro via the NOD2 receptor pathway and up-regulation of H3K4me3 histone methylation. However, these effects were less strong than those induced by live BCG. gBCG vaccination in volunteers had only minimal effects on innate immunity, whereas a significant increase in heterologous Th1/Th17 immunity was observed. Our results indicate that gBCG induces long-term training of innate immunity in vitro. In vivo, gBCG induces mainly heterologous effects on the adaptive-immune system, whereas effects on innate cytokine production are limited.
Introduction
The live-attenuated BCG vaccine protects against extrapulmonary infection with Mycobacterium tuberculosis and against leprosy [1, 2] . In addition, mounting evidence shows that vaccination with BCG has nonspecific, protective effects: early administration of BCG vaccination at birth leads to reduced child mortality, mainly as a result of reduced neonatal sepsis, respiratory infections, and fever [3] [4] [5] . Furthermore, BCG is used in patients with bladder cancer to induce immune-stimulating effects and slow tumor progression [6] , and the vaccine is also being investigated for potential protective effects against atopic diseases [7] .
Two main mechanisms have been suggested to mediate the nonspecific effects of BCG vaccination: potentiating effects on adaptive-immune responses ("heterologous immunity") and epigenetic reprogramming with functional priming of human monocytes (trained immunity) [8] [9] [10] . Upon stimulation with nonmycobacterial pathogens of cells isolated from BCGvaccinated individuals, both the adaptive-and the innateimmune systems demonstrate a primed status and are able to react faster and more efficient to a secondary (and nonrelated) stimulus [8, 9, 11] .
A major drawback of BCG being used for eliciting these effects clinically is that it is a live microorganism that cannot be used for vaccination in immunodeficient individuals (e.g., HIV-infected, postsepsis immunoparalysis) who are the group of patients most likely to profit from such effects [12] . If vaccination with gBCG would demonstrate similar potentiation of heterologous and/or trained immunity as with live BCG vaccine, it could be an attractive alternative. In this study, we investigated the nonspecific, long-term in vitro and in vivo effects of gBCG on the innate-and adaptive-immune responses.
MATERIALS AND METHODS

Subjects
The in vitro experiments were performed on cells isolated from healthy blood donors. For the in vivo BCG vaccination study, 15 healthy individuals (age range 20-34 yr, 9 women and six men) were included after informed consent had been given between November and December of 2013. One volunteer was lost to follow-up after 8 wk, as she moved abroad; therefore, the time point, 3 mo after vaccination, contains only data of 14 volunteers. Blood was drawn before, 2 wk, and 3 mo after vaccination with 0.075 mg gBCG. The study was approved by the Arnhem-Nijmegen Medical Ethical Committee and was registered at ClinicalTrials.gov as NCT02259608.
g-Irradiation
Vials with live-attenuated BCG (Statens Serum Institut, Copenhagen, Denmark) were irradiated in the original packaging with an average dose of at least 30 kGy [13, 14] in a JS6500 Tote Box Irradiator. g-Irradiation was performed by Synergy Health Ede B.V. (Ede, The Netherlands). The inactivated BCG was cultured for 6 wk to confirm inactivation.
In vitro monocyte stimulation
For the in vitro model of trained immunity, PBMCs were isolated by density gradient by use of Ficoll-Paque of buffy coats from healthy volunteers (Sanquin, Nijmegen, The Netherlands), after which monocytes were obtained by 1 h adherence and washing in 96-well, flat-bottom culture plates (5310 5 PBMCs/well in 100 ml vol). Monocytes were stimulated for 24 h with RPMI (control culture medium), live-attenuated BCG (10 mg/ml; Statens Serum Institut), heat-killed BCG (1 h at 100°C), or gBCG. In some experiments, the histone methyltransferase inhibitor MTA (1 mM; Sigma-Aldrich, St. Louis, MO, USA), a demethylase inhibitor pargyline (3 mM; Sigma-Aldrich), or Bartonella quintana LPS (a potent TLR4 antagonist [15] ; 20 ng/ml) was added. After 24 h, cells were washed with PBS to remove the stimuli, and cells were rested in RPMI 1640, supplemented with 10% human serum for 6 d. On d 7, monocytes were restimulated with different stimuli, including Escherichia coli LPS (10 ng/ml; Sigma-Aldrich), Pam3Cys (10 mg/ml; EMC Microcollections, Tuebingen, Germany), or heat-killed Staphylococcus aureus (1310 7 organisms/ml). In TLR4-blocking experiments, cells were restimulated with poly I:C (50 mg/ml; Invivogen, San Diego, CA, USA) and flagellin (5 mg/ml; Sigma-Aldrich) to assess non-TLR4-driven cytokine responses. After 24 h, supernatant was collected, and cytokines were measured by ELISA.
PBMC isolation and ex vivo stimulation of leukocytes isolated from the vaccinated volunteers
Isolation and stimulation were performed as described before [8, 9] . In brief, PBMCs were isolated from the healthy volunteers before and after BCG vaccination by density centrifugation of Ficoll-Paque and diluted to a concentration of 5 3 10 6 /ml. 
Cytokine measurements
Cytokine measurements were performed in the supernatants by use of commercial ELISA kits from R&D Systems (Minneapolis, MN, USA; TNF-a, IL-1b, IL-17, and IL-22) or Sanquin (Amsterdam, The Netherlands; IL-6 and IFN-g).
ChIP
To assess epigenetic markers associated with inflammatory changes, monocytes (10310 6 cells/well in 2 ml vol) were cultured in vitro in 6-well plates.
Cells were stimulated for 24 h with RPMI or gBCG (10 mg/ml), after which the stimuli were washed. After resting for 6 d in culture medium, the control and gBCG-primed cells were harvested and fixed in methanol-free formaldehyde 1%. Afterwards, cells were sonicated, and immunoprecipitation was performed by use of antibodies against H3K4me3 (Diagenode, Seraing, Belgium). After ChIP, DNA was processed further for qPCR analysis. Samples were analyzed by a comparative threshold method, in which myoglobin was used as a negative control and H2B as a positive control, according to the manufacturer's instructions. The following primers were used for this analysis: myoglobin forward AGCATGGTGCCACTGTGCT; myoglobin reverse GGCTTAATCTCTGCCTCATGAT; H2B forward TGTACTTGGTGACGGCCTTA; H2B reverse CATTACAACAAGCGCTCGAC; TNF forward GTGCTTGTTCCTCAGCCTCT; TNF reverse ATCACTCCAAAGTGCAGCAG; IL-6 forward AGGGAGAGCCAGAACACAGA; IL-6 reverse GAGTTTCCTCTGACTCCATCG.
Statistical analysis
Differences were analyzed by use of Wilcoxon signed-rank test or MannWhitney U test where applicable. All calculations were performed in GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA). P , 0.05 was considered statistically significant. Data are shown as means 6 SEM.
RESULTS
Inactivated BCG induces trained immunity in vitro
Preincubation of monocytes with live BCG and inactivated gBCG led to a significant 2-to 4-fold increase in IL-6 and TNF-a production upon restimulation with LPS 1 wk later compared with preincubation with culture medium only ( Fig. 1A and B) . Cytokine production directly after BCG stimulation did not differ between the different forms of BCG (data not shown).
Restimulation with Pam3Cys led to overall low cytokine responses; therefore, these data are not shown. Inactivation of BCG by g-irradiation or heat-killing had similar effects as live BCG, although in a lower magnitude ( Fig. 1C and D) . Cytokine levels in RPMI-restimulated samples were all below detection limit (data not shown).
Training of monocytes with gBCG is NOD2 dependent and not TLR4 dependent
To address the role of TLR2, TLR4, and NOD2 in BCGinduced, trained monocytes, the following experiments were performed. Firstly, the blocking of TLR4 or TLR2 by the addition of a potent TLR4 inhibitor (LPS derived from B. quintana) or an aTLR2 antibody during preincubation with live BCG and gBCG did not significantly influence the magnitude of trained immunity ( Fig. 2A-D) . Addition of B. quintana LPS alone did not lead to priming of cytokine responses (data not shown). Secondly, previous studies have shown an important role for NOD2 in the immune recognition of BCG and the induction of trained immunity by live BCG [8] .
A potential role of NOD2 for the induction of trained immunity by gBCG was validated by experiments showing that monocytes isolated from NOD2-deficient patients (homozygous for the 3020insC; rs2066847 mutation) have decreased induction of trained immunity when preincubated with gBCG and restimulated with LPS or Pam3Cys ( gBCG induces epigenetic changes in histone methylation associated with trained immunity. The effect of live BCG was stronger than that of gBCG ( Fig. 3A and B) . The importance of histone methylation for the induction of trained immunity was demonstrated further by the inhibition of live BCG and gBCG effects by the addition of a methyltransferase inhibitor MTA during the preincubation period. In contrast, the demethylase inhibitor pargyline had no effects on monocyte training ( Fig. 3C and D) .
Vaccination with gBCG induces heterologous immunity but not trained immunity in vivo
A group of healthy volunteers was vaccinated with gBCG to assess its effect on innate-and adaptive-immune responses. gBCG vaccination significantly increased the production of innateimmune cytokines IL-1b and IL-6, induced by M. tuberculosis, but not by the other microbial stimuli, showing that vaccination with inactivated BCG has only minimal effects on innate-immune responses (Fig. 4) .
In contrast, heterologous-immune responses represented by the production of IFN-g and IL-22 were significantly up-regulated 2 wk and 3 mo after vaccination with gBCG compared with baseline when restimulation was performed with S. aureus or C. albicans, demonstrating strong, nonspecific heterologous effects of gBCG (Fig. 4) . Surprisingly, the specific effect of gBCG was relatively weak, as the up-regulation of IFN-g production after M. tuberculosis stimulation was only increased marginally (Fig. 4) . As prevaccination, the IFN-g response to M. tuberculosis was low in all volunteers (which makes pre-exposure to mycobacterial antigens unlikely); this finding argues that gBCG cannot be used as a tuberculosis vaccine, as it will probably not induce enough immunologic protection, as shown previously [16] . After vaccination, cells of the volunteers were still capable of responding ex vivo to training by gBCG (Supplemental Fig. 1) .
Several studies have shown that among BCG-vaccinated children, those having a BCG scar have better survival than those without a scar [17, 18] . However, as all but 1 of the gBCG-vaccinated volunteers had developed a scar 3 mo after vaccination, we were not able to perform such an analysis.
DISCUSSION
In the present study we assessed the capacity of gBCG to stimulate heterologous and trained immunity, the 2 immunologic mechanisms believed to mediate the protective, nonspecific effects of BCG vaccination. Whereas gBCG induced trained immunity in an in vitro experimental model, this effect was less strong compared with the live-attenuated BCG vaccine. In line Figure 1 . BCG and gBCG priming of monocytes increases cytokine production upon restimulation with LPS. Adherent monocytes from healthy volunteers were incubated with gBCG (A), live BCG (B), or RPMI for 24 h, then washed with PBS, and rested for 6 d. On d 7, monocytes were rechallenged for 24 h with LPS, Pam3Cys, or culture medium. Cytokine production in supernatant was assessed with ELISA. Training cells with liveattenuated, heat-killed (hkBCG), and gBCG increased IL-6 (C) and TNF-a (D) production upon stimulation with LPS compared with priming with medium. Cytokine levels in RPMI-restimulated samples were all below the detection limit. Wilcoxon matched pairs signed-rank test; to compare fold changes between live BCG and gBCG, the Mann-Whitney test was used; n $ 6; *P , 0.05. with this, vaccination of healthy volunteers with gBCG had only limited effects on innate immunity. However, gBCG strongly potentiated heterologous Th1 and Th17 immunity, suggesting that this approach may have clinical applications.
A large body of epidemiologic studies, as well as a number of randomized clinical trials, reported significant, nonspecific, protective effects of BCG vaccination [3] [4] [5] [17] [18] [19] . Whereas very beneficial in young children and potentially also in the elderly [20] , BCG vaccination cannot be used in patients with immune deficiencies due to the fact that it contains live microorganisms. Therefore, it would be useful to explore alternative approaches that would avoid the danger of a disseminated infection in an immunocompromised host and also decrease side-effects as lymphadenitis in healthy persons, while retaining heterologous, beneficial effects on infection susceptibility. Thus, we hypothesized that g-irradiation of BCG, which kills the microorganism while preserving the structure of the cell wall, may be a viable alternative to the live vaccine.
The results of the in vitro and in vivo experiments reported here demonstrate a consistent pattern when comparing g-irradiated and live BCG. In in vitro models of trained immunity, gBCG was able to induce priming of monocytes toward increased cytokine production, but the effect was weaker than that of live BCG. As demonstrated previously with live vaccine [8] , gBCG induced these effects in a NOD2-dependent manner and was mediated by histone methylation at the level of H3K4. However, these effects were not strong enough to induce effective, trained immunity in vivo in all of the volunteers: the innate-immune responses were largely unaffected when assessed in the entire group, with the exception of M. tuberculosis-induced IL-1b and IL-6.
There are several possible reasons for the low effects of gBCG on trained immunity in vivo. Firstly, we cannot exclude that subtle changes of the mycobacterial cell wall were induced during irradiation, and that may result in partial loss of biologic activity. Differential effects of live and inactivated forms of BCG on TLR2 signaling and proinflammatory cytokine release have been noted in vitro before, showing a more potent effect of live BCG compared with inactivated forms [21] . Secondly, in vivo replication of BCG may be needed to release enough bacterial products (such as peptidoglycans that are recognized by NOD2) Figure 2 . Training with gBCG is dependent on the NOD2 receptor. TLR4 was blocked during priming with live BCG and gBCG by use of LPS derived from B. quintana (Bartonella); 1 wk later, cells were rechallenged with flagellin and poly I:C (pI:C). The blocking of TLR4 gave a nonsignificant increase of IL-6 (A) and TNF-a (B) production upon restimulation with flagellin. Depicted are fold changes compared with no training (n = 5). TLR2 was blocking during priming with live BCG and gBCG by use of an aTLR2 (aTLR2) antibody. One week later, cells were rechallenged with LPS. The blocking of TLR2 did not significantly influence IL-6 (C) and TNF-a (D) production upon restimulation with LPS. Depicted are fold changes compared with no training (n = 5). Adherent monocytes from NOD2-deficient patients and healthy controls were used in the in vitro training model. Macrophages from NOD2-deficient patients did not show increased IL-6 (E) and TNF-a (F) production upon restimulation with LPS, Pam3Cys (P3C), and S. aureus, 1 wk after training, whereas cells from healthy controls showed an up-regulation of cytokine production. Cytokine levels in RPMI-restimulated samples were below detection limit. Depicted is fold of change compared with no training (n = 4 patients vs. n = 4 controls). Mann-Whitney test was used for analysis of TLR4 blocking.
that would induce immunostimulatory effects at a distance [22, 23] . Finally, another possibility might be that the administered dose of gBCG, which was identical to that of the live vaccine, should have been increased to insure the same effect as observed with the live BCG vaccine. Multiple subsequent vaccinations could represent an alternative strategy to obtain the desired effect.
In contrast to the effects on the innate-immune system, gBCG vaccination induced strong, heterologous effects on the Th1 and Th17 response, as demonstrated by the clear increase in the production of IFN-g and IL-22 and to some extent, IL-17 upon stimulation of cells from vaccinated individuals with unrelated pathogens. Protective, heterologous effects of infections and vaccinations have been described before, for example, in mouse models where it has been shown that priming with 1 virus can enhance cytokine production and clearance of a second nonrelated virus [24, 25] . In addition, the immunization of mice with live BCG has been shown to enhance immunity against vaccinia virus, which was dependent on IFN-g production by CD4 cells [26] . Human vaccination with live-attenuated BCG has been shown to enhance Th1 responses of other vaccinations as well [27] . As a possible mechanism for heterologous effects on adaptive immunity, it has been shown that naturally occurring CD8 + T-lymphocytes expressing memory markers are able to produce rapidly vast amounts of IFN-g upon incubation with IL-12, which could be boosted by coincubation with IL-18, all in the absence of a pathogen [28, 29] . In addition, specific CD8 + T-lymphocytes were shown to produce IFN-g during an infection with a nonrelated pathogen [30] , and furthermore, CD4 + T-lymphocytes can produce IFN-g upon stimulation with IL-12 in an antigen-independent manner [31, 32] . Similar mechanisms have been envisaged for the increased Th17 response:
PstS1, a mycobacterial lipoprotein that has the same positive effect as BCG in a bladder cancer mice model [33] , is able to induce an antigen-independent amplification of the IFN-g and IL-17/IL-22 response. When PstS1-induced memory CD4 + T-lymphocytes were incubated with activated DCs, in the absence of a pathogen, increased production of IFN-g, IL-17, and IL-22 by the memory T-lymphocytes was observed, which was partly dependent on IL-6 production of the DCs [34] . These studies demonstrate several putative mechanisms through which heterologous Th1 and Th17 responses to nonrelated pathogens can be boosted after vaccination with gBCG. In our study, unfortunately, we have not analyzed which type of cell was the main producer of IFN-g or IL-17/22 in the ex vivo stimulation experiments. However, it can be hypothesized that memory T cells induced by gBCG vaccination are the source of increased Th1/Th17 responses upon stimulation with a nonrelated pathogen. Future studies are warranted to evaluate these biologic processes in human volunteers with gBCG vaccination.
In conclusion, in this study, we report that gBCG induces strong, heterologous effects on Th1/Th17 immunity, and these effects could be harnessed for the therapy of immunocompromised patients. Although probably not useful in HIV-infected patients with very low CD4 counts, in other clinical situations, in which T-lymphocytes are still present (such as postsepsis immunoparalysis and HIV-infected patients with CD4 counts higher than 200/mm 3 ), vaccination with gBCG may represent a novel strategy to boost the immune system and increase the resistance of the host to infections, thus potentially limiting morbidity and mortality in these vulnerable groups of patients. Although vaccination with the standard dose of gBCG induced only poorly trained immunity in vivo, higher or repeated dosages may represent additional Figure 3 . Training induced by gBCG is epigenetically mediated. Adherent monocytes were trained in vitro with gBCG. On d 6, cells were harvested and processed for ChIP. qPCR was performed on ChIPed DNA. Depicted is H3K4me 3% of total input for the IL-6 (A) and TNF-a promoter (B). Preincubation with gBCG led to increased H3K4me3 of TNF-a and IL-6 promoter region. Wilcoxon matched pairs signed-rank test; n = 8; *P , 0.05; **P , 0.01. In a separate set of experiments, the histone methyltransferase inhibitor MTA or the demethylase inhibitor pargyline was added during the first 24 h, while incubating with gBCG. After 1 wk, monocytes were rechallenged by use of LPS. Incubation with MTA abrogated the induction of IL-6 (C) and TNF-a (D) after training with live BCG and gBCG, whereas incubation with pargyline did not lead to an altered cytokine response. Depicted are fold changes compared with no training. Mann-Whitney test; n = 6; *P , 0.05. possible strategies to be explored in the future to increase the efficacy of this novel approach.
